WallStreetZenWallStreetZen

NASDAQ: KNTE
Kinnate Biopharma Inc Stock

$2.66+0.00 (+0%)
Updated Mar 28, 2024
KNTE Price
$2.66
Fair Value Price
$0.57
Market Cap
$125.62M
52 Week Low
$1.04
52 Week High
$7.19
P/E
-1.1x
P/B
0.79x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$112.65M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.09
Operating Cash Flow
-$100M
Beta
1.52
Next Earnings
Mar 29, 2024
Ex-Dividend
N/A
Next Dividend
N/A

KNTE Overview

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how KNTE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

KNTE ($2.66) is overvalued by 367.38% relative to our estimate of its Fair Value price of $0.57 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
KNTE ($2.66) is not significantly undervalued (367.38%) relative to our estimate of its Fair Value price of $0.57 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KNTE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KNTE due diligence checks available for Premium users.

Be the first to know about important KNTE news, forecast changes, insider trades & much more!

KNTE News

Valuation

KNTE fair value

Fair Value of KNTE stock based on Discounted Cash Flow (DCF)
Price
$2.66
Fair Value
$0.57
Overvalued by
367.38%
KNTE ($2.66) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KNTE ($2.66) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KNTE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

KNTE price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.1x
Industry
14.26x
Market
44.51x

KNTE price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.79x
Industry
6.21x
KNTE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

KNTE's financial health

Profit margin

Revenue
$0.0
Net Income
-$17.1M
Profit Margin
0%
KNTE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$173.6M
Liabilities
$14.3M
Debt to equity
0.09
KNTE's short-term assets ($158.18M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KNTE's short-term assets ($158.18M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KNTE's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
KNTE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$17.4M
Investing
$22.7M
Financing
$0.0
KNTE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

KNTE vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
KNTE$125.62M0.00%-1.10x0.79x
VIGL$125.78M+6.56%-1.60x1.08x
SEER$123.07M-2.06%-1.41x0.31x
CLRB$128.40M+9.49%-1.28x-94.68x
OCEA$128.97M-6.77%-0.93x-15.35x

Kinnate Biopharma Stock FAQ

What is Kinnate Biopharma's quote symbol?

(NASDAQ: KNTE) Kinnate Biopharma trades on the NASDAQ under the ticker symbol KNTE. Kinnate Biopharma stock quotes can also be displayed as NASDAQ: KNTE.

If you're new to stock investing, here's how to buy Kinnate Biopharma stock.

What is the 52 week high and low for Kinnate Biopharma (NASDAQ: KNTE)?

(NASDAQ: KNTE) Kinnate Biopharma's 52-week high was $7.19, and its 52-week low was $1.04. It is currently -62.98% from its 52-week high and 155.77% from its 52-week low.

How much is Kinnate Biopharma stock worth today?

(NASDAQ: KNTE) Kinnate Biopharma currently has 47,225,312 outstanding shares. With Kinnate Biopharma stock trading at $2.66 per share, the total value of Kinnate Biopharma stock (market capitalization) is $125.62M.

Kinnate Biopharma stock was originally listed at a price of $39.03 in Dec 3, 2020. If you had invested in Kinnate Biopharma stock at $39.03, your return over the last 3 years would have been -93.18%, for an annualized return of -59.15% (not including any dividends or dividend reinvestments).

How much is Kinnate Biopharma's stock price per share?

(NASDAQ: KNTE) Kinnate Biopharma stock price per share is $2.66 today (as of Mar 28, 2024).

What is Kinnate Biopharma's Market Cap?

(NASDAQ: KNTE) Kinnate Biopharma's market cap is $125.62M, as of Mar 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Kinnate Biopharma's market cap is calculated by multiplying KNTE's current stock price of $2.66 by KNTE's total outstanding shares of 47,225,312.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.